Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
    • CME
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Novel Assay Technologies

Lab-on-a-chip companion diagnostics for personalized management of breast cancer

Archana raamanathan and John McDevitt
Archana raamanathan
University of Texas, Austin, Austin, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John McDevitt
University of Texas, Austin, Austin, TX
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published October 2008
  • Article
  • Info & Metrics
Loading
AACR International Conference: Molecular Diagnostics in Cancer Therapeutic Development-- Sep 22-25, 2008; Philadelphia, PA

Abstract

B25

Breast cancer is the second leading cause of death among women in the United States. In 2008, an estimated 182,460 new cases will be diagnosed and 40,480 women will die of breast cancer.
HER 2 is a receptor tyrosine kinase oncogene product over-expressed in 30% of breast cancers. HER 2 targeted therapy (Trastuzumab®) has been FDA approved for breast cancer. The extracellular form (ECD) of HER 2 is shed into serum and HER 2 testing has been approved by the FDA to identify eligible metastatic breast cancer patients for Trastuzumab® treatment and follow-up and monitoring of patients with metastatic breast cancer. The promise of personalized medicine in breast cancer is not only to be able to recruit patients for target specific therapy but also to monitor subsequent treatment effectiveness.
In this work, we demonstrate the capability of our Lab-on-a-chip (LOC) multi-analyte biosensor platform in tailoring to the needs of the personalized medicine cancer diagnostics arena. For this proof-of-concept study, we have developed a first generation companion diagnostics chip for HER 2. We also demonstrate multiplexing ability of our platform with a proof-of-concept multiplex assay of HER 2 with CA 125 (prognostic marker for ovarian cancer).
The LOC sensor array platform performs chemical and immunological reactions on and within the interior regions of micro-spheres positioned in the inverted pyramidal micro-chamber wells of a silicon microchip. Micro-fluidic structures deliver a series of small-volume reagents and washes to the chip and to each of the micro-spheres. Optical signals generated by the reactions on the microspheres are visualized by, a charge-coupled device (CCD) video chip along with the use of trans-wafer optics. Using the LOC system, we have developed ultra sensitive sandwich ELISA type immunological assays for these tumor biomarkers. These immunoassays can be performed with small sample volumes and short assay times, and markedly reduced reagent costs thereby enabling rapid, cost effective analysis, imperative for realizing companion diagnostics for delivering personalized therapeutic decisions.
The assays developed have excellent analytical characteristics comparable to commercially available methods and multiplexing abilities rendering them amenable to the development of companion diagnostics in cancer therapy. Future work will entail clinical validation of the assay developed. The lab-on-a-chip platform lends itself to other analyte classes and hence promises a multiplex approach that cuts across several classes of analytes. Access to personalized medicine on such rapid and low cost LOC platforms can truly deliver the promise of fitting ‘the right drug to the right patient’ instead of a ‘one size fits all’ approach. This work will set a precedent for developing future companion diagnostics to serve along with targeted cancer therapeutics.

Footnotes

  • Third AACR International Conference on Molecular Diagnostics in Cancer Therapeutic Development-- Sep 22-25, 2008; Philadelphia, PA

  • American Association for Cancer Research
Back to top
Clinical Cancer Research: 14 (19 Supplement)
October 2008
Volume 14, Issue 19 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Lab-on-a-chip companion diagnostics for personalized management of breast cancer
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
Citation Tools
Lab-on-a-chip companion diagnostics for personalized management of breast cancer
Archana raamanathan and John McDevitt
Clin Cancer Res October 1 2008 (14) (19 Supplement) B25;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Lab-on-a-chip companion diagnostics for personalized management of breast cancer
Archana raamanathan and John McDevitt
Clin Cancer Res October 1 2008 (14) (19 Supplement) B25;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Novel Assay Technologies

  • Development and preclinical modeling of a topoisomerase I pharmacodynamic immunoassay for use in clinical trials
  • High throughput, quantitative DNA methylation screening using a quantum dot based nanotechnology assay
Show more 3

Novel Assay Technologies: Poster Presentations - Proffered Abstracts

  • Development and preclinical modeling of a topoisomerase I pharmacodynamic immunoassay for use in clinical trials
  • High throughput, quantitative DNA methylation screening using a quantum dot based nanotechnology assay
  • Lab-on-a-chip companion diagnostics for personalized management of breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement